Cure Forward Names Consumer Healthcare And IT Veteran Frank Ingari As CEO

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Cure Forward, the leading digital platform empowering cancer patients to identify targeted therapies and clinical trials, today announced the appointment of Frank Ingari as CEO. This appointment comes at a time of rapid growth for the company, which began operating its beta website earlier this year.

“Our families, our industry, and our country need to prove the efficacy of these new treatments. I’m honored to lead Cure Forward in our mission to help patients find their own best path in consultation with their doctors.”

Mr. Ingari has served the consumer, healthcare and information technology industries for the past 35 years. He previously held CEO appointments at NaviNet, 5-Star Medicare Advantage plan Essence Healthcare, and Best-in-KLAS Value-Based Care Service Provider Lumeris, which Ingari co-founded. His leadership capabilities have resulted in notable successes across numerous high-growth companies.

As CEO of Navinet, Ingari was instrumental in driving strategic growth for the nation's leading healthcare technology supplier of payer-provider collaboration solutions, culminating in a sale to NantHealth in January 2016.

Previously, under Ingari’s leadership, Essence Health pioneered an innovative accountable care solution with Lumeris Corporation to deliver world-class population management tools, clinical informatics, and information delivery systems to its members and contracted physicians.

“We are pleased to name Frank Ingari as Cure Forward’s CEO. Frank has a proven track record of driving transformational growth within the companies he leads,” said Seth Harrison, Chairman of the Board for Cure Forward and Managing Partner of New York-based Apple Tree Partners.

“Cure Forward moves beyond the ‘one-size-fits-all’ paradigm for cancer treatment and represents the first real opportunity for patients to explore new treatment options. We are thrilled to work with Frank and the Cure Forward team to fundamentally change the way patients access precision medicine.”

There are thousands of active clinical studies for cancer patients in the US today, but searching for the right trial places a significant burden on patients and their care teams. Data suggest fewer than 85% of patients are aware of potential trial options, and only 3% enroll in them. At the same time, advances in molecular science and immunology are introducing a steady stream of promising, innovative treatments tailored for individual patient needs.

“Patients facing multiple rounds of chemo or an unusual diagnosis often feel lost and discouraged. Navigating cancer can be bewildering for patients and their care teams. Cure Forward helps patients and their caregivers manage the unfamiliar territory of genomic and proteomic testing, test reimbursement, and clinical trial discovery. We help patients to connect with new treatments emerging now as part of the great wave of innovation stemming from the sequencing of the human genome fifteen years ago,” said CEO Frank Ingari.

“Our families, our industry, and our country need to prove the efficacy of these new treatments. I’m honored to lead Cure Forward in our mission to help patients find their own best path in consultation with their doctors.”

For more information, please visit www.cureforward.com.

About Cure Forward

Cure Forward is a multi-sided patient activation platform solving critical business needs for clinical trial recruiters, health care providers, and diagnostic laboratories. The company enables cancer patients and their care teams to use scientific data to access precision medicine and find targeted treatment options. At no cost to consumers, Cure Forward’s Clinical Trial Exchange (CTX) presents de-identified patient profiles to trial recruiters at biotech and pharma companies, clinical trial sites, CROs, and healthcare systems. Cure Forward launched its beta in 2016 after being incubated and funded by Apple Tree Partners, New York, NY. The company is based in Cambridge, Massachusetts.